GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipella Pharmaceuticals Inc (NAS:LIPO) » Definitions » Ending Cash Position

Lipella Pharmaceuticals (Lipella Pharmaceuticals) Ending Cash Position : $2.11 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Lipella Pharmaceuticals Ending Cash Position?

Lipella Pharmaceuticals's Ending Cash Position for the quarter that ended in Mar. 2024 was $2.11 Mil.

Lipella Pharmaceuticals's quarterly Ending Cash Position increased from Sep. 2023 ($2.41 Mil) to Dec. 2023 ($3.29 Mil) but then declined from Dec. 2023 ($3.29 Mil) to Mar. 2024 ($2.11 Mil).

Lipella Pharmaceuticals's annual Ending Cash Position increased from Dec. 2021 ($1.41 Mil) to Dec. 2022 ($5.12 Mil) but then declined from Dec. 2022 ($5.12 Mil) to Dec. 2023 ($3.29 Mil).

Lipella Pharmaceuticals Ending Cash Position Historical Data

The historical data trend for Lipella Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipella Pharmaceuticals Ending Cash Position Chart

Lipella Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Ending Cash Position
0.61 1.41 5.12 3.29

Lipella Pharmaceuticals Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.02 3.11 2.41 3.29 2.11

Lipella Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Lipella Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=5.121+-1.827
=3.29

Lipella Pharmaceuticals's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=3.293+-1.188
=2.11

Lipella Pharmaceuticals Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Lipella Pharmaceuticals's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Lipella Pharmaceuticals (Lipella Pharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipella Pharmaceuticals Inc (NAS:LIPO) » Definitions » Ending Cash Position
Comparable Companies
BWV BCLI PYPD ERNA JAGX IMPL PULM APM TTNP EMMA OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
7800 Susquehanna Street, Suite 505, Pittsburgh, PA, USA, 15208
Website
https://www.lipella.com
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's lead product candidates include LP-10 and LP-310.
Executives
Lori Birder director C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Daniel R Cohen director C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
David S. Battleman director C/O TRUENORTH LIFESCIENCES, 348 WEST 57TH STREET, #226, NEW YORK NY 10019
Byong Kim director C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Jonathan H Kaufman director, 10 percent owner, officer: See Remarks C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Ryan Pruchnic director C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Douglas Johnston officer: Chief Financial Officer C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Michael B Chancellor director, 10 percent owner, officer: Chief Medical Officer C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Naoki Yoshimura director C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208